Sparked by a flurry of executive orders in the first week of taking power, and evolving at dizzying pace, the new US administration has taken a wrecking ball to health-related services and research ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

As many as 140,000 bereaved parents, children and siblings of infected blood scandal victims may claim compensation under new ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

The most commonly used agents in the treatment of chronic hepatitis B include the nucleoside and nucleotide analogs. These are oral agents that target DNA synthesis and HBV polymerase activity ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

HealthDay News — For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and hepatocellular carcinoma (HCC), according to a review published online ...